Research Article
BibTex RIS Cite

The Role of BCG Immunotherapy in The Treatment of Superficial Bladder Tumor

Year 1996, Volume: 1 Issue: 2, 20 - 22, 30.12.1996

Abstract










28 patients with histologically proven superficial (pTa, pTl) transitional
cell carcinoma of the bladder were given intravesical prophylactic BCG for
prophylaxis protocol between May 1992- January 1995. Weekly instillation's' of
120 mg Connaught- BCG were given for a total of 6 weeks without additional
maintenance administrations. Followup period ranged between 3-32 months (mean
12.8). There were 2 recurrences within the first year of follow-up and the
recurrence rate was found as 0.55. The most common side effects were vesical
irritability and hematuria. We believe that longer follow up period and larger
series are needed for more reliable conclusion but the preliminary results of
BCG 
prophylaxis were encouraging.

References

  • Fradet Y. Markers of prognosis in superficial bladder cancer. Semin Urol 1992;10(1):28-38.
  • Morales A, Eidinger D; Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116(2):180-183. doi: 10.1016/s0022-5347(17)58737-6
  • Brosman SA. Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol. 1982;128(1):27-30. doi: 10.1016/s0022-5347(17)52736-6
  • Herr HW, Landone VP, Badalament RA. Experience with intravesical BCG therapy of superficial bladder tumors. Urology. 1985;25(2):119-124.
  • Pagona F, Bassi P, Milani C, Meneghini A, Maruzzi D, Garbeglio A. A low dose BCG regimen in superficial bladder cancer therapy: Is it effective? J Urol. 1991;146(1):32-35. doi: 10.1016/s0022-5347(17)37707-8
  • Carol PR. Urethelial carcinoma of the bladder. In: Tanagho EA, Mc Aaninch WJ, ed. Smith's General Urology. Lebanon:Appleton and Lange;1995:362-363.
  • Lamm DL, Crawford ED, Blumenstein BA. Maintenance BCG immunotherapy of superficial bladder cancer. A randomised prospective South west Oncology Group. J Urol. 1992;147:4.
  • Lamm DL. Complications of Bacillus Calmette- Guerin immunotherapy. Urol Clin North Am. 1992;19(3):565-572.
  • Lamm DL. Optimal treatment of superficial bladder cancer in 1994. Can J Urol. 1995;2(Supp l):l-6.
  • Ekşioğlu K, Müslümanoğlu A, Gültepe V, ve ark. Yüzeyel mesane tümorlerinde Tiotepa-Mitomycin-C ve BCG profilaksisi. Turkish Journal of Urology. 1993;19(3):226-231.
  • Mansuroğlu B, Saçak V, Ergün C, Tokuç R, Ünlüer E. Yüzeysel mesane tümoründe intravezikal epirubisin ve BCG profilaksisi. Turkish Journal of Urology. 1995;21(2):121-125.
  • Özyurt C, Cal C, Günaydın G, Nazlı O, Cüreklibatır İK, Erhan Ö. Yüzeysel mesane tümörlerinde iki değişik intravezikal BCG tedavi protokolünün karşılaştırılması. Urology Bulletin. 1995;6(4):217-220.

BCG İmmünoterapisinin Yüzeyel Mesane Tümörü Tedavisindeki Rolü

Year 1996, Volume: 1 Issue: 2, 20 - 22, 30.12.1996

Abstract










1992 Mayıs ve 1995 Ocak ayları arasında histolojik olarak pTa, pTl degişici
epitel hücreli mesane kanseri tanısı konulmuş 28 olgu intravezikal Bacillus
Calmette-Guerin (BCG) profilaksi programına alınmıştır. Haftada bir 6 hafta
instillasyon ile mesane içerisine 120 mg Connaught-BCG verilmiştir. Takip
suresi 3-32 ay arasında değişmekte olup ortalama 12.8 aydır. İlk bir yıl içinde
2 olguda nüks görüldü ve tümor nüks hızı 0.55 olarak tespit edildi. En sık yan
etki olarak mesane irritabilitesi ve hematüri gözlendi. Sonuç olarak daha güvenli
neticeler için daha büyük seriler ve daha uzun takip sürelerine ihtiyaç olmasına
rağmen intravezikal BCG profilaksisinin ön sonuçlarının cesaret verici olduğu gözlemlendi.

References

  • Fradet Y. Markers of prognosis in superficial bladder cancer. Semin Urol 1992;10(1):28-38.
  • Morales A, Eidinger D; Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116(2):180-183. doi: 10.1016/s0022-5347(17)58737-6
  • Brosman SA. Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol. 1982;128(1):27-30. doi: 10.1016/s0022-5347(17)52736-6
  • Herr HW, Landone VP, Badalament RA. Experience with intravesical BCG therapy of superficial bladder tumors. Urology. 1985;25(2):119-124.
  • Pagona F, Bassi P, Milani C, Meneghini A, Maruzzi D, Garbeglio A. A low dose BCG regimen in superficial bladder cancer therapy: Is it effective? J Urol. 1991;146(1):32-35. doi: 10.1016/s0022-5347(17)37707-8
  • Carol PR. Urethelial carcinoma of the bladder. In: Tanagho EA, Mc Aaninch WJ, ed. Smith's General Urology. Lebanon:Appleton and Lange;1995:362-363.
  • Lamm DL, Crawford ED, Blumenstein BA. Maintenance BCG immunotherapy of superficial bladder cancer. A randomised prospective South west Oncology Group. J Urol. 1992;147:4.
  • Lamm DL. Complications of Bacillus Calmette- Guerin immunotherapy. Urol Clin North Am. 1992;19(3):565-572.
  • Lamm DL. Optimal treatment of superficial bladder cancer in 1994. Can J Urol. 1995;2(Supp l):l-6.
  • Ekşioğlu K, Müslümanoğlu A, Gültepe V, ve ark. Yüzeyel mesane tümorlerinde Tiotepa-Mitomycin-C ve BCG profilaksisi. Turkish Journal of Urology. 1993;19(3):226-231.
  • Mansuroğlu B, Saçak V, Ergün C, Tokuç R, Ünlüer E. Yüzeysel mesane tümoründe intravezikal epirubisin ve BCG profilaksisi. Turkish Journal of Urology. 1995;21(2):121-125.
  • Özyurt C, Cal C, Günaydın G, Nazlı O, Cüreklibatır İK, Erhan Ö. Yüzeysel mesane tümörlerinde iki değişik intravezikal BCG tedavi protokolünün karşılaştırılması. Urology Bulletin. 1995;6(4):217-220.
There are 12 citations in total.

Details

Primary Language Turkish
Subjects Urology
Journal Section Research Articles
Authors

Nazım Mutlu This is me

Melih Çulha This is me

Birsen Mutlu This is me

Murat Baykal This is me

Erkan Merder This is me

Publication Date December 30, 1996
Submission Date August 1, 1996
Published in Issue Year 1996 Volume: 1 Issue: 2

Cite

AMA Mutlu N, Çulha M, Mutlu B, Baykal M, Merder E. BCG İmmünoterapisinin Yüzeyel Mesane Tümörü Tedavisindeki Rolü. Acta Med Nicomedia. December 1996;1(2):20-22.

images?q=tbn:ANd9GcSZGi2xIvqKAAwnJ5TSwN7g4cYXkrLAiHoAURHIjzbYqI5bffXt&s

The articles in the Journal of "Acta Medica Nicomedia" are open access articles licensed under a Creative Commons Attribution-ShareAlike 4.0 International License at the web address https://dergipark.org.tr/tr/pub/actamednicomedia